These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17169673)

  • 1. Common questions in managing hyperlipidemia.
    Rosen IM; Sams RW
    Prim Care; 2006 Dec; 33(4):903-21. PubMed ID: 17169673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying and managing patients with hyperlipidemia.
    Clark AB; Holt JM
    Am J Manag Care; 1997 Aug; 3(8):1211-9; quiz 1223-5. PubMed ID: 10170303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hospital-based network for hyperlipidaemia management and cardiovascular disease prevention.
    Pujia A;
    Nutr Metab Cardiovasc Dis; 2002 Aug; 12(4):198-203. PubMed ID: 12514940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical practice guidelines for the management of dyslipidemia.
    Nichols N
    Can J Cardiovasc Nurs; 2004; 14(2):7-10. PubMed ID: 15230023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dyslipidemia, diabetes and cardiovascular disease].
    Hansen CN; Jensen TJ; Borch-Johnsen K
    Ugeskr Laeger; 2000 Aug; 162(33):4367-70. PubMed ID: 10962957
    [No Abstract]   [Full Text] [Related]  

  • 6. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.
    Genest J; Frohlich J; Fodor G; McPherson R;
    CMAJ; 2003 Oct; 169(9):921-4. PubMed ID: 14581310
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins in the elderly: what evidence of their benefit in prevention?
    Steg PG; Tissot CM
    Arch Cardiovasc Dis; 2010 Feb; 103(2):61-5. PubMed ID: 20226424
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.
    Robson J
    Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in the management of hyperlipidemia-induced atherosclerosis.
    Tannock LR
    Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):369-83. PubMed ID: 18327996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dyslipidemias and cardiovascular diseases: towards a new perspective].
    Darioli R; Depairon M; Perdrix J; Mooser V
    Rev Med Suisse Romande; 2002 Oct; 122(10):489-93. PubMed ID: 12494781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hyperlipidemia in older adults.
    Alexander KP; Blazing MA; Rosenson RS; Hazard E; Aronow WS; Smith SC; Ohman EM
    J Cardiovasc Pharmacol Ther; 2009 Mar; 14(1):49-58. PubMed ID: 19124599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Blood lipid derangement common in peripheral artery disease. Lipid-lowering agents may alleviate symptoms and slow the atherosclerotic process].
    Bröijersén A; Wiklund B; Angelin B
    Lakartidningen; 2001 Sep; 98(36):3788-93. PubMed ID: 11586809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Statines for all or individualized lipid lowering therapy?].
    Parhofer K
    MMW Fortschr Med; 2009 Apr; 151(14):100, 102-4; quiz 105. PubMed ID: 19504849
    [No Abstract]   [Full Text] [Related]  

  • 15. Reducing CVD risk - integration of clinical and laboratory criteria.
    Tognarini DP; Sullivan DR; Thomas DW; Sikaris K
    Aust Fam Physician; 2008 Jun; 37(6):422-7. PubMed ID: 18523695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. K/DOQI gets to the heart of managing dyslipidemias in patients with CKD.
    Benner D
    Nephrol Nurs J; 2005; 32(3):337-8. PubMed ID: 16035475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing dyslipidemia in adults with diabetes.
    Haffner SM
    Manag Care; 2003 Sep; 12(9 Suppl):10-5. PubMed ID: 14535130
    [No Abstract]   [Full Text] [Related]  

  • 18. Reducing drug usage and adverse effects. Part III: Cardiovascular disease and hyperlipidemia.
    Baron M
    Health Care Food Nutr Focus; 2005 Jun; 22(6):7-11. PubMed ID: 15923907
    [No Abstract]   [Full Text] [Related]  

  • 19. The editor's roundtable: expanded versus standard lipid panels in assessing and managing cardiovascular risk.
    Sulkes D; Brown BG; Krauss RM; Segrest JP; Sniderman AD; Roberts WC
    Am J Cardiol; 2008 Mar; 101(6):828-42. PubMed ID: 18328849
    [No Abstract]   [Full Text] [Related]  

  • 20. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.
    Fodor JG; Frohlich JJ; Genest JJ; McPherson PR
    CMAJ; 2000 May; 162(10):1441-7. PubMed ID: 10834048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.